Saturday 17 October 2026
Export ZEPP’s income statement to Excel — free account
Zepp Health Corporation Sponsored ADR
ZEPP Technology Consumer Electronics
Zepp Health Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $258.9 million, up 41.8% from fiscal 2024. In the quarter to June 2026, revenue grew 6.93%, EPS fell 46.9%, free cash flow fell 103.7% and total debt rose 26.4%, each against the same quarter a year earlier.
3.04
0.16
−5.00%
Follow ZEPP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.30 | 0.70 | 1.65 | 3.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 194.68 | |
P/Operating CF |
(3.21) | (7.38) | (16.67) | (29.69) | |
P/B ratio |
0.45 | 0.98 | 2.00 | 3.20 | |
Price to Tangible BV |
0.51 | 1.11 | 2.24 | 3.57 | |
EV/Sales |
0.40 | 0.79 | 1.66 | 3.13 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.14) | (15.87) | (32.02) | 49.18 | |
EV/FCF |
(9.31) | (18.15) | (36.61) | 196.12 | |
Quick Ratio |
0.60 | 0.56 | 0.65 | 0.67 | |
Current Ratio |
0.90 | 0.88 | 1.02 | 1.09 | |
Net Debt/EBITDA |
(2.19) | (1.35) | (0.59) | (6.08) | |
Debt/Assets |
23.81% | 23.85% | 20.40% | 18.58% | |
Debt/Equity |
0.72 | 0.65 | 0.54 | 0.48 | |
Asset Turnover |
0.50 | 0.52 | 0.47 | 0.40 | |
Operating CF/Net income |
0.00 | 0.00 | 2.34 | 0.00 | |
Capex/Depreciation |
— | — | (0.09) | — | |
Interest Coverage |
(7.33) | (10.70) | (2.40) | (0.60) | |
Research and Development Expense of Revenue |
18.17% | 25.48% | 12.89% | 14.25% | |
Selling, General and Administrative Expense of Revenue |
38.55% | 46.55% | 32.06% | 25.08% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(1.12) | (0.42) | (0.13) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(52.78%) | (21.09%) | (9.32%) | (8.98%) | |
Free Cash Flow Yield |
(14.26%) | (6.20%) | (2.75%) | 0.51% | |
Revenue per Share |
4.01 | 3.25 | 5.36 | 4.79 | |
Operating CF per Share |
0.00 | 0.00 | (1.62) | 0.00 | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (1.64) | 0.00 | |
Cash per Share |
6.71 | 6.50 | 7.10 | 6.55 | |
Shareholders Equity per Share |
11.68 | 12.23 | 13.49 | 14.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.68 | 12.23 | 13.49 | 14.31 | |
Free Cash Flow |
— | — | (26.08) | — | |
Working Capital |
(31.86) | (35.00) | 6.68 | 25.84 | |
Capital Expenditures |
— | — | (0.39) | — | |
Net Current Asset Value |
(92.19) | (79.17) | (56.78) | (48.32) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
78.58 | 58.94 | 69.60 | 66.29 | |
Average Payables |
87.25 | 59.99 | 65.92 | 68.62 | |
Average Inventory |
71.17 | 63.49 | 64.77 | 82.13 | |
Average Assets |
554.32 | 525.67 | 546.71 | 587.61 | |
Average Common Equity |
205.18 | 213.10 | 233.63 | 270.94 |
Columns are period end dates